Compare REED & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REED | TNON |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 7.8M |
| IPO Year | 2009 | 2021 |
| Metric | REED | TNON |
|---|---|---|
| Price | $0.91 | $5.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.7K | ★ 2.1M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 84.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $34,065,000.00 | $3,944,000.00 |
| Revenue This Year | $18.74 | $65.95 |
| Revenue Next Year | $18.00 | $50.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 20.35 |
| 52 Week Low | $0.73 | $0.13 |
| 52 Week High | $5.97 | $17.84 |
| Indicator | REED | TNON |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | N/A |
| Support Level | $0.76 | N/A |
| Resistance Level | $1.42 | N/A |
| Average True Range (ATR) | 0.11 | 0.00 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 69.59 | 0.00 |
Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.
Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.